An observational study in Heart Valve Disease, TAVI and M-TEER, sponsored by Montreal Heart Institute. Recruiting at 15 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-09.
Sponsored by Montreal Heart Institute · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 48 studies in Heart Valve Diseases with a site in France — 16 open to participants now, 22 under way, 1 of them phase 3. Heart Valve Diseases · France.
Among the 48 studies in Heart Valve Diseases with a site in France, this one has the largest planned enrollment of the 17 observational ones that give a count, is one of 6 that started in 2024, is one of 17 observational ones, reaches primary completion later than 13 of the 21 other live ones, and was the 48th registered.
557 studies on the registry are indexed under Heart Valve Diseases; 167 are open to participants now.
Browse Heart Valve Diseases studies →16 of the 48 studies in Heart Valve Diseases with a site in France are open now. Recruiting first, the newest first:
University Hospital, Toulouse · Sites in France
Ages 18+
French Cardiology Society · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Nantes University Hospital · Sites in France
Ages 65+ · Healthy volunteers
Abbott Medical Devices · Sites in France, United States, Denmark and 7 more countries
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 119 Heart Valve Diseases studies recruiting now, 94 (79%) set no upper age limit and 10 (8%) stop at 75 or younger; 16 take children under 18; 15 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
48 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 3
First in 2002; this study’s year is marked. 6 started in 2024.
This study's planned enrollment of 21,000 is above the median of 300 across 228 observational studies indexed under Heart Valve Diseases.
Median enrollment 228 across the 31 interventional studies, 800 across the 17 observational. Of the 25 that completed or were terminated, 8 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 48 have an industry lead sponsor. The 10 most frequent:
Montreal Heart Institute is the lead sponsor of 101 studies on the registry; 23 are open to participants now.
Montreal Heart Institute has 2 studies filed under Heart Valve Diseases — fewer than ten, so there is no comparison to draw.
4 of the studies in Heart Valve Diseases with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06215378Phase 3Assistance Publique - Hôpitaux de ParisAntagonization of Heparin With Protamine Sulfate After TAVI | 2027-03-01 |
| NCT02747485Assistance Publique Hopitaux De MarseilleImpact of Diffuse Myocardial Fibrosis on the Ventricular Function in Regurgitant Left-Sided Valve Heart Diseases ( The DIFFUsE Study) | 2026-11 |
| NCT03142152Cardiac Dimensions, Inc.The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR | 2026-12-31 |
| NCT05932615Abbott Medical DevicesENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation | 2027-04 |
Add all 4 to your calendar (.ics) → With an account.
Among the 48 studies in Heart Valve Diseases with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This non-interventional study aims to use artificial intelligence to improve the prediction of transcatheter heart valve interventions and optimize patient outcomes. It is based on the analysis of retrospective data from various specialized centers worldwide.
The ENVISAGE study is a non-interventional, retrospective research study designed to validate an artificial intelligence (AI)-based framework for the automated analysis of cardiac imaging data, including multi-slice cardiac computed tomography (CT) and transesophageal echocardiography (TEE). The primary objective is to predict the success of transcatheter heart valve interventions, including aortic, mitral, and tricuspid valve interventions (TAVI, TMVI, M-TEER, T-TEER). The AI framework developed in this study will rely on deep learning algorithms, particularly convolutional neural networks (CNNs) and other advanced models, to automatically segment critical anatomical structures and perform accurate measurements of these structures from CT and TEE images. These measurements will then be combined with pre-interventional clinical data to optimize patient selection and intervention planning, as well as to predict surgical outcomes with high accuracy. AI will also aim to reduce human error and inter-observer variability in the interpretation of cardiac images, which could significantly improve clinical outcomes.
Patients with heart valve disease eligible for transcatheter interventions (TAVI, M-TEER, TMVI, TTVI).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients who have reached the age of legal majority under local laws.
For TAVI group: All patients who have had TAVI with a third generation transcatheter heart valve (THV), with an available pre-procedural optimal quality CT scan as defined by an - gating CT with:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All patients who have had TAVI with a third generation transcatheter heart valve (THV). Medical imaging data (CT, TEE) and preoperative clinical data will be collected for analysis.
Diagnostic Test: Medical imaging analysis via artificial intelligence algorithms
Patients who have had a TMVI with a dedicated transeptal device and screen failures. Medical imaging data (CT, TEE) and preoperative clinical data will be collected for analysis.
Diagnostic Test: Medical imaging analysis via artificial intelligence algorithms
Patients who have had a TTVI with a dedicated device and screen failures. Medical imaging data (CT, TEE) and preoperative clinical data will be collected for analysis.
Diagnostic Test: Medical imaging analysis via artificial intelligence algorithms
All patients who have had a M-TEER with 1) G4 or newer iteration of MitraClip or 2) G2 or newer iteration of Pascal. Medical imaging data (CT, TEE) and preoperative clinical data will be collected for analysis.
Diagnostic Test: Medical imaging analysis via artificial intelligence algorithms
All patients who have had a T-TEER with G4 or newer iteration of TriClip or 2) G2 or newer iteration of Pascal. Medical imaging data (CT, TEE) and preoperative clinical data will be collected for analysis.
Diagnostic Test: Medical imaging analysis via artificial intelligence algorithms
Development of AI algorithms based on pre-procedural imaging annotations and clinical informations to predict the transcatheter procedural outcomes
Accuracy of transcatheter AI predictions
Validation of artificial intelligence algorithms for automatic segmentation of anatomic structures and imaging measurements, and prediction of the success of transcatheter interventions. Output of AI algorithm: * Sizes, types, and number of devices to be implanted * Device success * Percentage risk of permanent pacemaker implantation (for TAVI and TTVI) * Percentage risk of 30-day (para)valvular regurgitation for TAVI, and residual regurgitation for M-TEER and T-TEER * Single leaflet detachment for M-TEER and T-TEER * Left ventricular outflow tract obstruction for TMVI. Key success indicators: * First, independent retrospective validation dataset AI algorithms predict procedural outcome with \>90% accuracy and low inter-reader observer variability when compared to measured procedural outcome. * Second independent retrospective dataset, perform a study to validate AI algorithms with \>90% accuracy and low inter-reader observer variability when compared to measured procedural outcome.
Time frame: Preoperative phase: automated segmentation and measurements compared with manual assessments; Postoperative phase at day 30: comparison of predicted results with actual clinical patient outcomes.
Performance of AI algorithms in CT and TEE image analysis
Development and evaluation of AI algorithm training platform for data analysis of patients undergoing transcatheter valve procedures. Comparison of AI model performance with existing benchmarks and manual analyses
Time frame: Through study completion, an average of 2 years (retrospective analysis and validation of algorithms).
AI-based discovery of clinical knowledge for patient selection
Comparison of AI's ability to standardize patient selection, treatment planning and clinical outcomes with traditional methods. Assessment of accuracy in predicting patient outcomes and reducing procedure-specific complications.
Time frame: Baseline (pre-procedural) and post-procedural (day 90) analysis
Plan to share: No
No publications or documents are linked to this record.
Started May 2024 (actual). Primary completion is estimated for May 2028, 48 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.